Abgenix Inc., of Fremont, Calif., named R. Scott Greer chairman of the board. Greer already serves as president and CEO.
Amgen Inc., of Thousand Oaks, Calif., named Steven Odre senior vice president, general counsel and secretary.
Anika Therapeutics Inc., of Woburn, Mass., promoted Charles Sherwood to vice president, research and development.
Argonaut Technologies Inc., of San Carlos, Calif., named to its scientific advisory board Jean Frechet, a professor of chemistry at the University of California at Berkeley, and Robert Waymouth, a professor of chemistry at Stanford University.
CIStem Molecular Corp., of San Diego, named Mary Harper chief scientific officer.
Discovery Technologies Ltd., of San Diego, named Greg Sabbatini director of business development and marketing, North America.
DNA Dynamics Inc., of Del Mar, Calif., named Tina Nova president and CEO.
EluSys Therapeutics Inc., of Pine Brook, N.J., named David Jackson vice president of research and development.
Genset, of Paris, named John Varian chief financial officer, and Philippe Rousseau vice president, finance.
Illumina Inc., of San Diego, named Timothy Kish vice president and chief financial officer; David Barker vice president and chief scientific officer; Robert Kain vice president of engineering; and Noemi Espinosa vice president of intellectual property.
ImClone Systems Inc., of New York, elected to its board of directors Arnold Levine, president of The Rockefeller University.
Incyte Genomics Inc., of Palo Alto, Calif., appointed David Briscoe president of Incyte Genomics Ltd.
Inhibitex Inc., of Alpharetta, Ga., named Juan Walterspiel vice president of clinical and regulatory affairs.
NeoRx Corp., of Seattle, elected to its board of directors Carl Goldfischer, chief financial officer of New York-based ImClone Systems Inc.
Nymox Pharmaceutical Corp., of Maywood, N.J., named Allan Reimer vice president for technology acquisition and development.
SangStat Medical Corp., of Fremont, Calif., appointed Elliott Grossbard senior vice president, medical development.
Sepracor Inc., of Marlborough, Mass., appointed Jack Britts vice president, marketing and commercial planning.
Sonus Pharmaceuticals Inc., of Bothell, Wash., promoted Richard Klein to vice president of finance and controller.
Sunesis Pharmaceuticals Inc., of Redwood City, Calif., named Daryl Winter senior vice president and general counsel.
Theratechnologies, of Montreal, appointed to its scientific board Christopher Bredson and William Burns, both of the Medical College of Wisconsin; Richard Champlin, of the M.D. Anderson Cancer Center in Houston; Nelson Chao, of the Duke University Medical Center in Raleigh, N.C.; and Arnold Freedman, of the Dana-Farber Cancer Institute in Boston. Also named to the board were Lothar Huebsch, of Ottawa Hospital in Ontario; Scott Rowley, of the Fred Hutchinson Cancer Research Center in Seattle; John Sweetenham, of the Southampton General Hospital in Southampton, UK; and Catherine Verfaillie, of the University of Minnesota.
Variagenics Inc., of Cambridge, Mass., named Edward Koval senior director, business development; Beverly Holley senior director, investor relations; Karyn Finamore general counsel; and Mary McWeeney director of human resources.
ViaMed Inc., of Fremont, Calif., appointed to its board of directors Michael Ellwein, vice president and chief development officer of Medtronic Inc.
Xanthon Inc., of Research Triangle Park, N.C., appointed to its scientific advisory board James O'Connell, vice president of business development of Nanogen Inc. and named James O'Connell vice president of business development.
Zila Inc., of Phoenix, named Thomas Laughlin chief operating officer.